Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Short term Debt (2016 - 2025)

China Pharma Holdings filings provide 16 years of Short term Debt readings, the most recent being $2.0 million for Q4 2025.

  • On a quarterly basis, Short term Debt rose 72.69% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 72.69% increase, with the full-year FY2025 number at $2.0 million, up 72.69% from a year prior.
  • Short term Debt hit $2.0 million in Q4 2025 for China Pharma Holdings, up from $2.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $4.3 million in Q3 2021 to a low of $940173.0 in Q1 2025.
  • Median Short term Debt over the past 5 years was $2.0 million (2021), compared with a mean of $2.2 million.
  • Biggest five-year swings in Short term Debt: soared 112.48% in 2022 and later plummeted 66.73% in 2023.
  • China Pharma Holdings' Short term Debt stood at $4.3 million in 2021, then plummeted by 43.61% to $2.4 million in 2022, then crashed by 57.77% to $1.0 million in 2023, then rose by 11.09% to $1.1 million in 2024, then soared by 72.69% to $2.0 million in 2025.
  • The last three reported values for Short term Debt were $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.